Figure 4.
(a) PFS in patients with and without liver metastases; (b) PFS in patients with and without brain metastases; (c) PFS in patients with and without bone metastases; (d) PFS in patients treated with immunotherapy upfront or in subsequent lines; (e) PFS in different histologies; (f) PFS in patients affected by squamous and non-squamous NSCLC or other cancers.